ATE373016T1 - Induktion von immunologischer toleranz gegen einen therapeutischen antikörper durch varianten des therapeutischen antikörpers - Google Patents

Induktion von immunologischer toleranz gegen einen therapeutischen antikörper durch varianten des therapeutischen antikörpers

Info

Publication number
ATE373016T1
ATE373016T1 AT97905226T AT97905226T ATE373016T1 AT E373016 T1 ATE373016 T1 AT E373016T1 AT 97905226 T AT97905226 T AT 97905226T AT 97905226 T AT97905226 T AT 97905226T AT E373016 T1 ATE373016 T1 AT E373016T1
Authority
AT
Austria
Prior art keywords
therapeutic antibody
antibody
immunological tolerance
variants
induction
Prior art date
Application number
AT97905226T
Other languages
German (de)
English (en)
Inventor
Herman Waldmann
Lisa Gilliland
Masahide Tone
Mark Frewin
Louise Walsh
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation filed Critical Isis Innovation
Application granted granted Critical
Publication of ATE373016T1 publication Critical patent/ATE373016T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97905226T 1996-02-20 1997-02-20 Induktion von immunologischer toleranz gegen einen therapeutischen antikörper durch varianten des therapeutischen antikörpers ATE373016T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9603507.6A GB9603507D0 (en) 1996-02-20 1996-02-20 Antibody variants

Publications (1)

Publication Number Publication Date
ATE373016T1 true ATE373016T1 (de) 2007-09-15

Family

ID=10789047

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97905226T ATE373016T1 (de) 1996-02-20 1997-02-20 Induktion von immunologischer toleranz gegen einen therapeutischen antikörper durch varianten des therapeutischen antikörpers

Country Status (11)

Country Link
US (2) US20020048578A1 (enExample)
EP (1) EP0970127B1 (enExample)
JP (1) JP4574750B2 (enExample)
AT (1) ATE373016T1 (enExample)
AU (1) AU723366B2 (enExample)
CA (1) CA2246715C (enExample)
DE (1) DE69738138T2 (enExample)
ES (1) ES2294793T3 (enExample)
GB (1) GB9603507D0 (enExample)
NZ (1) NZ331299A (enExample)
WO (1) WO1997031024A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU725609C (en) * 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
ATE384792T1 (de) 1998-11-18 2008-02-15 Genentech Inc Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
CA2423850C (en) 2000-10-09 2017-07-04 Isis Innovation Limited Therapeutic antibodies
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US20040109855A1 (en) * 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
JPWO2004087210A1 (ja) * 2003-03-31 2006-06-29 麒麟麦酒株式会社 抗ｃｄ５２抗体による調節性ｔ細胞分化誘導・増殖方法およびそのための医薬組成物
NZ550815A (en) * 2004-05-19 2009-04-30 Immunocore Ltd Method of improving T cell receptors
JP2008532559A (ja) * 2005-03-19 2008-08-21 メディカル リサーチ カウンシル ウイルス感染の治療及び予防又は治療及び予防の改善
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
CN101820898B (zh) * 2007-05-16 2013-10-30 中国抗体制药有限公司 互补决定区（CDRs）功能人源化
WO2009025846A2 (en) 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
RU2636046C2 (ru) 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Композиции модифицированных антител, способы их получения и применения
EP2398494A4 (en) 2009-02-23 2015-10-28 Cytomx Therapeutics Inc Proproteins and their methods of use
JP5894912B2 (ja) 2009-05-13 2016-03-30 ジェンザイム・コーポレーション 抗ヒトｃｄ５２免疫グロブリン
US8685896B2 (en) 2009-05-29 2014-04-01 Morphosys Ag Collection and methods for its use
CN103237809B (zh) 2010-11-19 2016-09-07 莫佛塞斯公司 一个集合及其使用方法
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
WO2013152011A1 (en) * 2012-04-02 2013-10-10 Ab Biosciences, Inc. Novel human control antibodies and uses therefor
US9120853B2 (en) 2012-04-27 2015-09-01 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
KR20150139955A (ko) 2013-04-09 2015-12-14 보스톤 바이오메디칼, 인크. 암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온
WO2015066279A2 (en) 2013-10-30 2015-05-07 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2015089283A1 (en) 2013-12-11 2015-06-18 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
US20160120158A1 (en) * 2014-11-03 2016-05-05 The Johns Hopkins University Compositions and methods for the study and treatment of acute kidney injury
BR112017026025A2 (pt) 2015-06-03 2018-08-14 Boston Biomedical Inc composições que compreendem um inibidor de stemness de câncer e um agente imunoterápico para uso no tratamento de câncer
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
US10646464B2 (en) 2017-05-17 2020-05-12 Boston Biomedical, Inc. Methods for treating cancer
WO2020223273A2 (en) 2019-04-30 2020-11-05 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Compositions and methods for modulation of antibody activity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2216126B (en) * 1988-02-12 1992-06-03 Medical Res Council Antibodies to the antigen campath-1
US5846534A (en) * 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
US5858725A (en) * 1990-10-10 1999-01-12 Glaxo Wellcome Inc. Preparation of chimaeric antibodies using the recombinant PCR strategy
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE174515T1 (de) * 1991-10-15 1999-01-15 Btg Int Ltd Verwendung eines cdw52-spezifischen antikörpers zur behandlung von durch t-zellen vermittelten gelenkentzündungen
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method

Also Published As

Publication number Publication date
JP4574750B2 (ja) 2010-11-04
WO1997031024A1 (en) 1997-08-28
GB9603507D0 (en) 1996-04-17
EP0970127A1 (en) 2000-01-12
ES2294793T3 (es) 2008-04-01
AU723366B2 (en) 2000-08-24
DE69738138D1 (de) 2007-10-25
DE69738138T2 (de) 2008-06-05
JP2000506723A (ja) 2000-06-06
US20020048578A1 (en) 2002-04-25
US8440190B2 (en) 2013-05-14
US20060018898A1 (en) 2006-01-26
AU1885197A (en) 1997-09-10
EP0970127B1 (en) 2007-09-12
CA2246715A1 (en) 1997-08-28
NZ331299A (en) 2000-05-26
CA2246715C (en) 2008-08-05

Similar Documents

Publication Publication Date Title
DE69738138D1 (de) Induktion von immunologischer Toleranz gegen einen therapeutischen Antikörper durch Varianten des therapeutischen Antikörpers
DE60230029D1 (de) Immunisierungstherapie zur behandlung von atherosklerose
AT500379B1 (de) Tau-proteine
DE69433406T2 (de) Antikörper gegen cd40
ATE513563T1 (de) Therapeutische und toleranz-induzierende antikörper
DK1385864T3 (da) Anti-VEGF-2-antistoffer
ATE178907T1 (de) Rezeptorbindende region des diphtherietoxius
ATE414104T1 (de) Fragmente des menschlichen choriogonadotropin (hcg) als immunregulator
CY1109817T1 (el) Ολιγο-βητα-(1,3)-γλυκανη και μονοκλωνικα αντισωματα εναντιον καρκινου
DE60238533D1 (de) Nicht-depletierender Antikörper TRX-1 gegen CD4 und dessen Verwendungen
DE69530844D1 (de) Verfahren und substanzen gegen protozoen
EP1411962A4 (en) TREATMENT OF PANCREATIC CANCER WITH A MONOCLONAL ANTIBODY
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
EA200200974A1 (ru) Моноклональные антитела к рецептору лпнп человека, их получение и применение
DE69636527D1 (de) Antigenes protein aus malassezia
DE69118702D1 (de) Neue verwendung eines monoklonalen antikörpers
ATE108832T1 (de) Verwendung von monoklonalen antikörpern gegen b2- mikroglobulin.
DK0858465T3 (da) Protein med antitumorvirkning.
RU96123360A (ru) Способ лечения сепсиса у новорожденных

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties